Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) EBITDA (2017 - 2025)

VYNE Therapeutics' EBITDA history spans 9 years, with the latest figure at -$5.8 million for Q2 2025.

  • For Q2 2025, EBITDA rose 38.72% year-over-year to -$5.8 million; the TTM value through Jun 2025 reached -$38.5 million, down 35.12%, while the annual FY2025 figure was -$26.5 million, 33.48% up from the prior year.
  • EBITDA reached -$5.8 million in Q2 2025 per VYNE's latest filing, up from -$8.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$5.6 million in Q1 2023 to a low of -$12.1 million in Q3 2024.
  • Average EBITDA over 5 years is -$8.7 million, with a median of -$8.8 million recorded in 2021.
  • Peak YoY movement for EBITDA: skyrocketed 94.29% in 2021, then tumbled 95.33% in 2024.
  • A 5-year view of EBITDA shows it stood at -$8.8 million in 2021, then increased by 9.74% to -$8.0 million in 2022, then grew by 22.82% to -$6.2 million in 2023, then tumbled by 95.33% to -$12.0 million in 2024, then skyrocketed by 52.17% to -$5.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's EBITDA are -$5.8 million (Q2 2025), -$8.6 million (Q1 2025), and -$12.0 million (Q4 2024).